Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

Comment

Raffaele Landolfi et al. Lancet. 2002.

. 2002 Jul 20;360(9328):257.

doi: 10.1016/S0140-6736(02)09473-4.

No abstract available

Comment on

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
Simoons ML; GUSTO IV-ACS Investigators. Simoons ML, et al. Lancet. 2001 Jun 16;357(9272):1915-24. doi: 10.1016/s0140-6736(00)05060-1. Lancet. 2001. PMID: 11425411 Clinical Trial.
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Boersma E, et al. Lancet. 2002 Jan 19;359(9302):189-98. doi: 10.1016/S0140-6736(02)07442-1. Lancet. 2002. PMID: 11812552